Vivosbio (688321.SH): The Phase III clinical trial of the first-line treatment of Diffuse Large B-cell Lymphoma with Xitatinib obtained top-line analysis data.

Zhijing Financial APP News, MicroPort BioMedics (688321.SH) announced that the company's independently developed Sibutramine for the first-line treatment of diffuse large B-cell lymphoma (DLBCL) pivotal phase III clinical trial (DEB study) has recently received top-line analysis data of final results, with the experimental group showing significantly better event-free survival (EFS) compared to the control group, meeting the primary endpoint of the study.